162 related articles for article (PubMed ID: 35049019)
21. Edoxaban, a Novel Oral Factor Xa Inhibitor.
Minor C; Tellor KB; Armbruster AL
Ann Pharmacother; 2015 Jul; 49(7):843-50. PubMed ID: 25855704
[TBL] [Abstract][Full Text] [Related]
22. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Brekelmans M; Middeldorp S; Coppens M
Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
[TBL] [Abstract][Full Text] [Related]
23. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
Di Nisio M; Raskob G; Büller HR; Grosso MA; Zhang G; Winters SM; Cohen A
Thromb Haemost; 2017 Apr; 117(4):784-793. PubMed ID: 28151543
[TBL] [Abstract][Full Text] [Related]
24. Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide.
Ramacciotti E; Aguiar VCR; Júnior VC; Casella IB; Zerati AE; Fareed J
Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):340S-349S. PubMed ID: 30486661
[TBL] [Abstract][Full Text] [Related]
25. Managing pulmonary embolism from presentation to extended treatment.
Cohen AT; Dobromirski M; Gurwith MM
Thromb Res; 2014 Feb; 133(2):139-48. PubMed ID: 24182642
[TBL] [Abstract][Full Text] [Related]
26. ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months.
Agnelli G; Hoffmann U; Hainaut P; Gaine S; Ay C; Coppens M; Schindewolf M; Jimenez D; Brüggenjürgen B; Levy P; Laeis P; Fronk EM; Zierhut W; Malzer T; Manu MC; Reimitz PE; Bramlage P; Cohen AT;
Thromb Res; 2020 Dec; 196():297-304. PubMed ID: 32950897
[TBL] [Abstract][Full Text] [Related]
27. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.
Raskob GE; van Es N; Verhamme P; Carrier M; Di Nisio M; Garcia D; Grosso MA; Kakkar AK; Kovacs MJ; Mercuri MF; Meyer G; Segers A; Shi M; Wang TF; Yeo E; Zhang G; Zwicker JI; Weitz JI; Büller HR;
N Engl J Med; 2018 Feb; 378(7):615-624. PubMed ID: 29231094
[TBL] [Abstract][Full Text] [Related]
28. Current management of venous thromboembolism in Japan: Current epidemiology and advances in anticoagulant therapy.
Nakamura M; Yamada N; Ito M
J Cardiol; 2015 Dec; 66(6):451-9. PubMed ID: 25896176
[TBL] [Abstract][Full Text] [Related]
29. Recurrent venous thromboembolism during anticoagulation with edoxaban or warfarin: A post hoc analysis of the Hokusai-VTE trial.
Eichinger S; Lin M; Shi M; Grosso MA; Kyrle PA
Thromb Res; 2020 Nov; 195():209-214. PubMed ID: 32750571
[TBL] [Abstract][Full Text] [Related]
30. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
[TBL] [Abstract][Full Text] [Related]
31. Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
Barrios V; Escobar C
Future Cardiol; 2016 Jul; 12(4):419-33. PubMed ID: 27121025
[TBL] [Abstract][Full Text] [Related]
32. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
Preblick R; Kwong WJ; White RH; Goldhaber SZ
Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of long-term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis.
Serrao A; Merli M; Lucani B; Aprile F; Fiori L; Gioia S; Breccia M; Riggio O; Chistolini A
Eur J Clin Invest; 2021 Jan; 51(1):e13356. PubMed ID: 33180323
[TBL] [Abstract][Full Text] [Related]
35. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
Hillis C; Crowther MA
Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
[TBL] [Abstract][Full Text] [Related]
36. Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
Kubli KA; Snead JA; Cheng-Lai A
Cardiol Rev; 2016; 24(4):205-10. PubMed ID: 26991962
[TBL] [Abstract][Full Text] [Related]
37. Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register.
Palareti G; Legnani C; Antonucci E; Cosmi B; Falanga A; Poli D; Mastroiacovo D; Pengo V; Ageno W; Testa S
Ther Adv Drug Saf; 2021; 12():20420986211062965. PubMed ID: 34987749
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
39. New oral anticoagulants for the treatment of venous thromboembolism.
Agnelli G; Becattini C; Franco L
Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
[TBL] [Abstract][Full Text] [Related]
40. The use of factor Xa inhibitors following opening-wedge high tibial osteotomy for venous thromboembolism prophylaxis.
Kobayashi H; Akamatsu Y; Kumagai K; Kusayama Y; Ishigatsubo R; Mitsuhashi S; Kobayashi A; Aratake M; Saito T
Knee Surg Sports Traumatol Arthrosc; 2017 Sep; 25(9):2929-2935. PubMed ID: 27000391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
